ArticleJournal of family medicine and primary care2025
Outcome of immunosuppressive therapy in pediatric patients with acquired aplastic anemia.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the response to immunosuppressive therapy (IST) in children with acquired aplastic anemia (AAA) and factors affecting the outcome. Methods: Ambispective observational study was conducted from Aug 2022 to May 2024 prospectively. Records from June 2012 to July 2022 were analyzed for retrospective cases. Children 2-18 years meeting Camitta's criteria were included. Hematopoietic stem cell transplant (HSCT) was advised if feasible and affordable, rest were offered IST. They received IST with horse anti-thymocyte globulin (ATG) and cyclosporine. Thrombopoietin (TPO) agonists were used in few patients only. Response was assessed at 3 months and 6 months after IST. Results: Among 52 prospective cases 43 (83%) were AAA and 9 (17%) were Fanconi anemia (FA). Among 48 retrospective cases, 42 (87%) were AAA and 6 (12%) were FA. FA patients were excluded from analysis. Majority of patients were severe aplastic anemia (SAA) (37%) followed by very severe (VSAA) (32%) and non-severe aplastic anemia (NSAA) (30%). Overall response rate (ORR) was 58.8% with complete response (CR) of 35.3% and partial response (PR) of 23.0% in prospective group and CR of 55.2% and PR of 3.8% in retrospective group. SAA and NSAA patients responded 2.5 times better than VSAA patients to IST (RR = 2.514, 95% CI = 1.145-7.076). Other variables age, gender, duration of illness, duration from diagnosis to IST and type of IST had no correlation with outcome ( Conclusion: The ORR was found to be 58.8%, which is similar to published reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.